{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:13:47Z","timestamp":1791422027356,"version":"4.3.3"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["20-GSK-02"],"award-info":[{"award-number":["20-GSK-02"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,4,18]]},"abstract":"<jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activities of gepotidacin and comparator agents against 3,560\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            and 344\n            <jats:named-content content-type=\"genus-species\">Staphylococcus saprophyticus<\/jats:named-content>\n            collected from female (81.1%) and male (18.9%) patients with urinary tract infections (UTIs) in a global prospective surveillance program in 2019 to 2020 were determined. Isolates collected from 92 medical centers in 25 countries, including the United States, Europe, Latin America, and Japan, were tested for susceptibility by reference methods in a central monitoring laboratory.\n          <\/jats:p>","DOI":"10.1128\/aac.01525-22","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T14:01:54Z","timestamp":1678111314000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020)"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-6238","authenticated-orcid":true,"given":"S. J. Ryan","family":"Arends","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Butler","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":true,"given":"Nicole","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":true,"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.10.020"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0362-4"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1680052"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-21"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02095-16"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_3_13_2","unstructured":"ClinicalTrials.gov. 2021. A study to evaluate efficacy and safety of gepotidacin in the treatment of uncomplicated urinary tract infection (UTI): ClinicalTrials.gov identifier NCT04020341. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04020341."},{"key":"e_1_3_3_14_2","unstructured":"ClinicalTrials.gov. 2022. Comparative study to evaluate efficacy and safety of gepotidacin to nitrofurantoin in treatment of uncomplicated urinary tract infection (UTI): ClinicalTrials.gov identifier NCT04187144. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04187144."},{"key":"e_1_3_3_15_2","unstructured":"ClinicalTrials.gov. 2021. A study evaluating efficacy and safety of geptidacin compared with ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhea: ClinicalTrials.gov identifier NCT04010539. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010539."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00199-20"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2022-055518"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02245-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02047-16"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-17"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky162"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky255"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa034"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.002"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3627"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt368"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_3_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_30_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing. M100Ed32. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_31_2","volume-title":"Performance standards for antimicrobial disk susceptibility tests.","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial disk susceptibility tests. M02Ed13. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_32_2","unstructured":"EUCAST. 2022. Breakpoint tables for interpretation of MICs and zone diameters version 12.0 http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01525-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01525-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T13:05:04Z","timestamp":1681823104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01525-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,18]]}},"alternative-id":["10.1128\/aac.01525-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01525-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01525-22"}}